A. L. Vladykin
A. L. Vladykin has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander A. Globenko
Valenta Pharm JSC
5 shared publications - K. A. Ishchenko
JSC “Valenta Pharm
3 shared publications - Maxim V Zamergrad
Russian Medical Academy of Continuous Professional Education
3 shared publications - Vladimir Anatolyevich Parfenov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
3 shared publications - A. V. Kapashin
Valenta Pharm JSC
2 shared publications - Ekaterina Aleksandrovna Jain
А Valenta Pharm JSC
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 36-47
Comparative efficacy and safety of Vespireit® and Arlevert® in the treatment of patients with functional dizziness: results of an open-label multicenter randomized phase IV clinical trial
Functional dizziness (FD) is one of the most common causes of chronic dizziness. Objective: a comparative assessment of the efficacy and safety of Vespireit® (buspirone), 15 mg prolonged-release tablets, versus Arlevert® tablets (cinnarizine 20 mg + dimenhydrinate 40 mg) in the treatment of patients with FD. Material and methods. The clinical trial (CT) included 160 patients with FD and scores on the Dizziness Handicap Inventory (DHI) ≥31 points and the Mean Vertigo Score (MVS) ≥1.5 points, who were randomized into two groups. Patients in group 1 (n=80) received Vespireit at a dose of 15 mg (1 tablet) once daily for 28 days. Patients in group 2 (n=80) received Arlevert 1 tablet 3 times daily for 28 days. Treatment was administered against a background of vestibular gymnastics exercises. The primary efficacy endpoint (PEE) was the change in mean MVS score at visit 1-3 (day 28±1) compared with baseline (visit 1-1, day 1). Secondary efficacy endpoints (SEEs) included assessment compared with baseline (visit 1-1, day 1): 1) change in mean MVS score by visit 1-2 (day 7±1); 2) change in the proportion of patients with a ≥50% reduction in mean DHI score by visit 1-3; 3) change in mean score on the numerical rating scale (NRS) by visits 1-2 (day 7±1) and 1–3 (day 28±1); 4) assessment by patient and physician of clinical improvement in proportions of patients and mean scores on the Clinical Global Impression Scale-Improvement Scale (CGI-I) by visits 1-2 (day 7±1) and 1-3 (day 28±1). In case of recurrence (exacerbation of dizziness symptoms), a second course of treatment with the study drugs and a similar assessment using the scales were performed. At the end-of-study visit (day 365±7 from visit 1-1), the proportion of patients with recurrence and the duration of the remission period were assessed. Safety criteria included assessment of adverse events (AEs), clinically significant deviations in vital signs, laboratory parameters, and electrocardiography (ECG) parameters. Results. Assessment of the PEE revealed no significant differences between the groups (p=0.0814); the lower limit of the 95% confidence interval (-0.07 points) did not exceed the non-inferiority margin (-0.3), thus demonstrating non-inferior efficacy of Vespireit compared with Arlevert. Assessment of most SEEs showed a statistically significant advantage of therapy in group 1 compared with group 2: reduction in mean MVS score by visit 1-2 (p=0.0427); proportion of responders with ≥50% reduction in mean DHI score by visit 1-3 (p=0.0433); reduction in mean NRS score by visits 1-2 (p=0.0230) and 1-3 (p=0.12244); proportion of responders with marked improvement (1 point) and considerable improvement (2 points) on CGI-I by visits 1-2 and 1-3 (patient assessment p=0.0453 and p=0.0481, p=0.0101 and p=0.8584; physician assessment p=0.0725 and p=0.0321, p=0.0169 and p=0.8622). A similar anti-relapse effect was established in groups 1 and 2 [proportion of patients without recurrence in group 1 – 94.87% (n=74), in group 2 – 93.67% (n=74; p=1.0000); duration of remission in group 1 – 359.14±38.08 days, in group 2 – 361.33±15.77 days (p=0.1798)]. A total of 84 AEs were recorded in 35 (21.88%) patients: 52 AEs in 18 (22.5%) patients in group 1 and 32 AEs in 17 (21.25%) in group 2. No significant difference was found between the groups in the number of patients with AEs (p=0.8483). During the CT, no serious adverse events (SAEs), fatal SAEs, or AEs leading to discontinuation of therapy were recorded. No clinically significant deviations from normal were observed in the assessment of vital and laboratory parameters or ECG parameters. Conclusion. Assessment of the PEE demonstrated non-inferior efficacy, and for a number of SEEs, superiority of therapy with Vespireit over therapy with Arlevert was established in reducing manifestations of FD. The drugs demonstrated a comparably high level of anti-relapse effect and a favorable safety profile.
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 36-47
Open AccessComparative efficacy and safety of Vespireit® and Arlevert® in the treatment of patients with functional dizziness: results of an open-label multicenter randomized phase IV clinical trial
Functional dizziness (FD) is one of the most common causes of chronic dizziness. Objective: a comparative assessment of the efficacy and safety of Vespireit® (buspirone), 15 mg prolonged-release tablets, versus Arlevert® tablets (cinnarizine 20 mg + dimenhydrinate 40 mg) in the treatment of patients with FD. Material and methods. The clinical trial (CT) included 160 patients with FD and scores on the Dizziness Handicap Inventory (DHI) ≥31 points and the Mean Vertigo Score (MVS) ≥1.5 points, who were randomized into two groups. Patients in group 1 (n=80) received Vespireit at a dose of 15 mg (1 tablet) once daily for 28 days. Patients in group 2 (n=80) received Arlevert 1 tablet 3 times daily for 28 days. Treatment was administered against a background of vestibular gymnastics exercises. The primary efficacy endpoint (PEE) was the change in mean MVS score at visit 1-3 (day 28±1) compared with baseline (visit 1-1, day 1). Secondary efficacy endpoints (SEEs) included assessment compared with baseline (visit 1-1, day 1): 1) change in mean MVS score by visit 1-2 (day 7±1); 2) change in the proportion of patients with a ≥50% reduction in mean DHI score by visit 1-3; 3) change in mean score on the numerical rating scale (NRS) by visits 1-2 (day 7±1) and 1–3 (day 28±1); 4) assessment by patient and physician of clinical improvement in proportions of patients and mean scores on the Clinical Global Impression Scale-Improvement Scale (CGI-I) by visits 1-2 (day 7±1) and 1-3 (day 28±1). In case of recurrence (exacerbation of dizziness symptoms), a second course of treatment with the study drugs and a similar assessment using the scales were performed. At the end-of-study visit (day 365±7 from visit 1-1), the proportion of patients with recurrence and the duration of the remission period were assessed. Safety criteria included assessment of adverse events (AEs), clinically significant deviations in vital signs, laboratory parameters, and electrocardiography (ECG) parameters. Results. Assessment of the PEE revealed no significant differences between the groups (p=0.0814); the lower limit of the 95% confidence interval (-0.07 points) did not exceed the non-inferiority margin (-0.3), thus demonstrating non-inferior efficacy of Vespireit compared with Arlevert. Assessment of most SEEs showed a statistically significant advantage of therapy in group 1 compared with group 2: reduction in mean MVS score by visit 1-2 (p=0.0427); proportion of responders with ≥50% reduction in mean DHI score by visit 1-3 (p=0.0433); reduction in mean NRS score by visits 1-2 (p=0.0230) and 1-3 (p=0.12244); proportion of responders with marked improvement (1 point) and considerable improvement (2 points) on CGI-I by visits 1-2 and 1-3 (patient assessment p=0.0453 and p=0.0481, p=0.0101 and p=0.8584; physician assessment p=0.0725 and p=0.0321, p=0.0169 and p=0.8622). A similar anti-relapse effect was established in groups 1 and 2 [proportion of patients without recurrence in group 1 – 94.87% (n=74), in group 2 – 93.67% (n=74; p=1.0000); duration of remission in group 1 – 359.14±38.08 days, in group 2 – 361.33±15.77 days (p=0.1798)]. A total of 84 AEs were recorded in 35 (21.88%) patients: 52 AEs in 18 (22.5%) patients in group 1 and 32 AEs in 17 (21.25%) in group 2. No significant difference was found between the groups in the number of patients with AEs (p=0.8483). During the CT, no serious adverse events (SAEs), fatal SAEs, or AEs leading to discontinuation of therapy were recorded. No clinically significant deviations from normal were observed in the assessment of vital and laboratory parameters or ECG parameters. Conclusion. Assessment of the PEE demonstrated non-inferior efficacy, and for a number of SEEs, superiority of therapy with Vespireit over therapy with Arlevert was established in reducing manifestations of FD. The drugs demonstrated a comparably high level of anti-relapse effect and a favorable safety profile.
- Open Access
- 19 April 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (11-12) , 41-48
Study of the Safety and Toxicokinetic Parameters of the Drug Eladis® in Preclinical Trials with Repeated Administration
Cough is one of the most common reasons for initial visits to healthcare providers, affecting 40–50% of patients with viral respiratory tract infections. Treatment options for cough include medications that block signal transmission at the central or peripheral level of the reflex arc, as well as mucolytic and expectorant agents. Valenta Pharm JSC has developed an innovative drug, Eladis® (film-coated tablets, 20 mg and 40 mg), intended for the treatment of cough in patients with acute respiratory infections. The aim of the present study was to assess the safety profile and toxicokinetic parameters of the drug after repeated administrations. In the study conducted on mature rabbits, the drug was administered orally at doses of 1, 3, or 6 tablets/animal over 28 days, corresponding to 13.3, 40, and 80 mg/kg, respectively. No signs of intoxication were observed in any of the experimental groups. To evaluate toxicokinetic parameters, blood samples were collected from the marginal ear vein after the 1st and 28th days of administration. Both single and multiple (28-day) administrations of the drug showed a statistically significant increase in Cmax and AUC0–24 with increasing doses. No drug accumulation was observed following repeated administration on day 28. In a separate study on juvenile rats, Eladis® was administered intragastrically for 30 days at doses of 11.8, 118, and 236 mg/kg. The results indicated no significant effects of the drug on body weight gain, animal behavior in a battery of functional tests, as well as the estimated physiological, biochemical, and hematological parameters. The drug demonstrated no local irritant or immunotoxic effects and had no impact on spermatogenesis.
- 19 April 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (11-12) , 41-48
Open AccessStudy of the Safety and Toxicokinetic Parameters of the Drug Eladis® in Preclinical Trials with Repeated Administration
Cough is one of the most common reasons for initial visits to healthcare providers, affecting 40–50% of patients with viral respiratory tract infections. Treatment options for cough include medications that block signal transmission at the central or peripheral level of the reflex arc, as well as mucolytic and expectorant agents. Valenta Pharm JSC has developed an innovative drug, Eladis® (film-coated tablets, 20 mg and 40 mg), intended for the treatment of cough in patients with acute respiratory infections. The aim of the present study was to assess the safety profile and toxicokinetic parameters of the drug after repeated administrations. In the study conducted on mature rabbits, the drug was administered orally at doses of 1, 3, or 6 tablets/animal over 28 days, corresponding to 13.3, 40, and 80 mg/kg, respectively. No signs of intoxication were observed in any of the experimental groups. To evaluate toxicokinetic parameters, blood samples were collected from the marginal ear vein after the 1st and 28th days of administration. Both single and multiple (28-day) administrations of the drug showed a statistically significant increase in Cmax and AUC0–24 with increasing doses. No drug accumulation was observed following repeated administration on day 28. In a separate study on juvenile rats, Eladis® was administered intragastrically for 30 days at doses of 11.8, 118, and 236 mg/kg. The results indicated no significant effects of the drug on body weight gain, animal behavior in a battery of functional tests, as well as the estimated physiological, biochemical, and hematological parameters. The drug demonstrated no local irritant or immunotoxic effects and had no impact on spermatogenesis.
- 15 November 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (10) , 60-68
Pathogenetic therapy of cognitive impairment: results of a multicenter placebo-controlled clinical trial of the efficacy and safety of Miladean
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка эффективности и безопасности применения препарата Миладеан в терапии пациентов с когнитивными нарушениями (КН) сосудистого генеза (хроническая ишемия головного мозга, ХИМ). МАТЕРИАЛ И МЕТОДЫ В ходе двойного слепого многоцентрового проспективного рандомизированного клинического исследования III фазы с плацебо-контролем (двойное слепое) и активным контролем (открытое) 300 пациентов с КН на фоне ХИМ были рандомизированы в 3 группы: 1-я группа (n=100) получала Миладеан (суточная доза: мемантин 10 мг + мелатонин 6 мг), 2-я группа (n=101) — мемантин (10 мг/сут), 3-я группа — плацебо (n=99) в течение 8 нед. Оценивали динамику общего балла (первичный критерий эффективности) и долю пациентов с улучшением по шкале Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog), динамику нарушений зрительно-пространственной ориентации (тест Бентона), качество сна (шкала Pittsburgh Sleep Quality Index) и безопасность терапии. РЕЗУЛЬТАТЫ На фоне применения Миладеана показано статистически и клинически значимое снижение общего балла по шкале ADAS-Cog (на 6,1 против 4,7 и 3,5 балла во 2-й (p=0,009) и 3-й (pp=0,019 и pp=0,026), качество сна (84,7% пациентов с КН), превосходя плацебо (63,9%) и мемантин (64,3%) (p=0,002 в обоих случаях). Миладеан хорошо переносился, случаев взаимодействия с препаратами базовой терапии не зарегистрировано. ЗАКЛЮЧЕНИЕ Сочетание в Миладеане множества различных патогенетических эффектов позволяет предположить наличие у него способности замедлять скорость прогрессирования КН и стабилизировать состояние пациентов. Уникальная комбинация действующих веществ в составе Миладеана эффективна и безопасна в терапии пациентов с КН.
- 15 November 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (10) , 60-68
Pathogenetic therapy of cognitive impairment: results of a multicenter placebo-controlled clinical trial of the efficacy and safety of Miladean
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка эффективности и безопасности применения препарата Миладеан в терапии пациентов с когнитивными нарушениями (КН) сосудистого генеза (хроническая ишемия головного мозга, ХИМ). МАТЕРИАЛ И МЕТОДЫ В ходе двойного слепого многоцентрового проспективного рандомизированного клинического исследования III фазы с плацебо-контролем (двойное слепое) и активным контролем (открытое) 300 пациентов с КН на фоне ХИМ были рандомизированы в 3 группы: 1-я группа (n=100) получала Миладеан (суточная доза: мемантин 10 мг + мелатонин 6 мг), 2-я группа (n=101) — мемантин (10 мг/сут), 3-я группа — плацебо (n=99) в течение 8 нед. Оценивали динамику общего балла (первичный критерий эффективности) и долю пациентов с улучшением по шкале Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog), динамику нарушений зрительно-пространственной ориентации (тест Бентона), качество сна (шкала Pittsburgh Sleep Quality Index) и безопасность терапии. РЕЗУЛЬТАТЫ На фоне применения Миладеана показано статистически и клинически значимое снижение общего балла по шкале ADAS-Cog (на 6,1 против 4,7 и 3,5 балла во 2-й (p=0,009) и 3-й (pp=0,019 и pp=0,026), качество сна (84,7% пациентов с КН), превосходя плацебо (63,9%) и мемантин (64,3%) (p=0,002 в обоих случаях). Миладеан хорошо переносился, случаев взаимодействия с препаратами базовой терапии не зарегистрировано. ЗАКЛЮЧЕНИЕ Сочетание в Миладеане множества различных патогенетических эффектов позволяет предположить наличие у него способности замедлять скорость прогрессирования КН и стабилизировать состояние пациентов. Уникальная комбинация действующих веществ в составе Миладеана эффективна и безопасна в терапии пациентов с КН.
- Open Access
- 23 October 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (5) , 20-34
Efficacy and safety of Vespireit® (buspirone) prolonged-release tablets (PR) 15 mg in the therapy of patients with functional dizziness: results of the double-blind, placebo-controlled, multicenter, randomized, phase 3 clinical trial
Functional dizziness (FD) is one of the most common causes of chronic dizziness for which there is no effective drug therapy, highlighting the importance of searching for new treatment technologies.Objective: to evaluate the efficacy and safety of Vespireit® (INN buspirone) prolonged-release tablets 15 mg2 (JSC “Valenta Pharm”, Russia) compared with placebo in the treatment of patients with autonomic dysfunction syndrome accompanied by FD.Material and methods. The clinical trial (CT) included a total of 268 patients with autonomic dysfunction syndrome accompanied by FD and a DHI (The Dizziness Handicap Inventory) dizziness scale score of 36 to 52 inclusive, who were randomly divided into 2 groups and treated in a double-blind fashion. 135 patients (Group 1) received Vespireit® prolonged-release tablets 15 mg at a dose of 15 mg (1 tablet) once daily for 28 days. 133 patients (Group 2) received placebo at the same dosage regimen. Treatment was given against a background of vestibular gymnastic exercises. The primary outcome of the clinical trial was assessment of patient response rate (proportion of responders), i.e., a ≥50% reduction in total DHI for dizziness score at Visit 5 (day 28±1) compared with baseline (Visit 1, day 1). Secondary efficacy measures included assessment of: 1) treatment response rates (≥50% reduction in DHI total score compared to Visit 1) at Visits 2, 3, and 4; 2) DHI total score at Visits 2, 3, 4, and 5; 3) changes in DHI total score at Visits 2, 3, 4, and 5 compared to Visit 1; 4) proportion of patients with a 30% or greater reduction in DHI scale dizziness compared with baseline at Visit 2, 3, 4, and 5; 5) time elapsed until total DHI score decreased by ≥50% compared to baseline; 6) time elapsed until total DHI score decreased by ≥30% compared to baseline; 7) changes in Digital Rating Scale (DRS) score from Visit 1 to Visit 2, 3, 4, 5; 8) scores on the DRS at Visits 2, 3, 4, 5; 9) proportion of patients with different response to treatment on the Likert scale at Visits 2, 3, 4, and 5. Additional secondary criteria of efficacy were also assessed: total Hamilton Depression Rating Scale (HDRS) score at Visits 4 and 5; change in total Hamilton scale score at Visits 4 and 5 compared to Visit 1. The safety criterion assessed in the clinical trial was monitoring of adverse events (AEs), clinically significant deviations in vital signs, laboratory parameters, and ECG parameters.Results. The proportion of responders with a ≥50% reduction in DHI total score at Visit 5 (Day 28±1) compared to baseline (Visit 1, Day 1) was 68.7% (n=92) in Group 1, which was 52.9% more than in Group 2 – 15.8% (n=21) (pConclusion. The superiority of Vespireit® prolonged-release tablets (PR) 15 mg therapy over placebo in reducing FD in patients with autonomic dysfunction syndrome was confirmed. The drug demonstrated a favorable safety profile comparable to placebo.
- 23 October 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (5) , 20-34
Open AccessEfficacy and safety of Vespireit® (buspirone) prolonged-release tablets (PR) 15 mg in the therapy of patients with functional dizziness: results of the double-blind, placebo-controlled, multicenter, randomized, phase 3 clinical trial
Functional dizziness (FD) is one of the most common causes of chronic dizziness for which there is no effective drug therapy, highlighting the importance of searching for new treatment technologies.Objective: to evaluate the efficacy and safety of Vespireit® (INN buspirone) prolonged-release tablets 15 mg2 (JSC “Valenta Pharm”, Russia) compared with placebo in the treatment of patients with autonomic dysfunction syndrome accompanied by FD.Material and methods. The clinical trial (CT) included a total of 268 patients with autonomic dysfunction syndrome accompanied by FD and a DHI (The Dizziness Handicap Inventory) dizziness scale score of 36 to 52 inclusive, who were randomly divided into 2 groups and treated in a double-blind fashion. 135 patients (Group 1) received Vespireit® prolonged-release tablets 15 mg at a dose of 15 mg (1 tablet) once daily for 28 days. 133 patients (Group 2) received placebo at the same dosage regimen. Treatment was given against a background of vestibular gymnastic exercises. The primary outcome of the clinical trial was assessment of patient response rate (proportion of responders), i.e., a ≥50% reduction in total DHI for dizziness score at Visit 5 (day 28±1) compared with baseline (Visit 1, day 1). Secondary efficacy measures included assessment of: 1) treatment response rates (≥50% reduction in DHI total score compared to Visit 1) at Visits 2, 3, and 4; 2) DHI total score at Visits 2, 3, 4, and 5; 3) changes in DHI total score at Visits 2, 3, 4, and 5 compared to Visit 1; 4) proportion of patients with a 30% or greater reduction in DHI scale dizziness compared with baseline at Visit 2, 3, 4, and 5; 5) time elapsed until total DHI score decreased by ≥50% compared to baseline; 6) time elapsed until total DHI score decreased by ≥30% compared to baseline; 7) changes in Digital Rating Scale (DRS) score from Visit 1 to Visit 2, 3, 4, 5; 8) scores on the DRS at Visits 2, 3, 4, 5; 9) proportion of patients with different response to treatment on the Likert scale at Visits 2, 3, 4, and 5. Additional secondary criteria of efficacy were also assessed: total Hamilton Depression Rating Scale (HDRS) score at Visits 4 and 5; change in total Hamilton scale score at Visits 4 and 5 compared to Visit 1. The safety criterion assessed in the clinical trial was monitoring of adverse events (AEs), clinically significant deviations in vital signs, laboratory parameters, and ECG parameters.Results. The proportion of responders with a ≥50% reduction in DHI total score at Visit 5 (Day 28±1) compared to baseline (Visit 1, Day 1) was 68.7% (n=92) in Group 1, which was 52.9% more than in Group 2 – 15.8% (n=21) (pConclusion. The superiority of Vespireit® prolonged-release tablets (PR) 15 mg therapy over placebo in reducing FD in patients with autonomic dysfunction syndrome was confirmed. The drug demonstrated a favorable safety profile comparable to placebo.
- Open Access
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 53-65
Evaluation of pharmacokinetic parameters, safety and tolerability of single and multiple doses of Vespireit®: results of phase I clinical trial.
Objective: to evaluate the pharmacokinetic parameters, safety and tolerability of Vespireit® (INN buspirone), prolonged-release tablets, 15 mg (JSC “Valenta Pharm”, Russia), which is being developed as a drug for the treatment of functional vertigo, in healthy volunteers with a single oral dose of 15 and 30 mg on an empty stomach or after meals and multiple doses in a daily dose of 15 mg.Material and methods. JSC “Valenta Pharm” conducted an open-label, three-stage, randomized, two-periods, cross-over comparative clinical trial of Vespireit®. At stages 1 and 2, healthy volunteers were screened and randomized into two equal groups (Group 1 and Group 2), as well as the distribution of participants in Group 3. Then, at stage 1, healthy volunteers (n=24) took Vespireit® once at a dose of 15 mg on an empty stomach or after meals, at stage 2, volunteers (n=24) took Vespireit® once at a dose of 30 mg on an empty stomach or after meals. Stage 3 was conducted in 18 volunteers as a non-randomized, non-comparative study with Vespireit® 15 mg on an empty stomach once daily for 5 days. During the study, blood samples were collected from each subject to determine the concentration of test compounds in blood plasma and subsequently calculate their pharmacokinetic parameters. Quantitative determination of buspirone and its two metabolites, 6-hydroxybuspirone (6OH-bus) and 1-(2-pyrimidinyl)-piperazine (1-PP), was performed by a validated high-performance liquid chromatography method with tandem mass spectrometric detection. During the study, tolerability and safety were also evaluated: adverse events, vital signs, laboratory parameters and electrocardiogram parameters were recorded.Results. When the study drug Vespireit®, prolonged-release tablets, was administered once at a dose of 15 mg to healthy volunteers after a meal, an increase in the relative bioavailability and relative degree of absorption of buspirone was observed compared with the fasting state, which was accompanied by a 1.5- and 2.5-fold increase in the AUC0–t and Cmax of buspirone, respectively. In addition, the Cmax of 6-OH-bus increased 1.4-fold and the Cmax of 1-PP increased 1.2-fold. Meal had no effect on the AUC0–t of 6-OH-bus and 1-PP. When the study drug was administered once at a dose of 30 mg after a meal, an increase in the relative bioavailability and relative degree of absorption of buspirone was observed compared with fasting, which was accompanied by an increase in the AUC0–t and Cmax by 1.5- and 2.1-fold, respectively. A 1.2-fold increase in the Cmax of 6-OH-bus was also observed. Food had no effect on the AUC0–t of 6-OH-bus and on the AUC0–t and Cmax of 1-PP. No accumulation of buspirone and its metabolites was observed with repeated dosing.Conclusion. In the study, the values of pharmacokinetic parameters of the new drug Vespireit® in the prolonged-release tablets dosage form were determined both with single administration on an empty stomach and after meals and with multiple administration. The differences and advantages over buspirone preparations in the form of immediate-release tablets are shown: higher relative bioavailability of buspirone with a reduction in interindividual differences in bioavailability and Cmax, more stable plasma concentration of buspirone with reduced peak values of the active substance and metabolite 1-PP, a 1.2-fold increase in AUC0–∞, a 2-fold increase in T1/2, and a 2-fold increase in the degree of retardation (MRT) for buspirone, a 1.4-fold increase in Cmax and MRT of 6-OH-bus, a decrease in AUC0–∞, AUC0–t, and T1/2 of metabolite 1-PP, and a decrease in the ratio of the concentration of 1-PP to the concentration of buspirone and to 6-OH-bus. A favorable safety profile of Vespireit® was demonstrated.
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 53-65
Open AccessEvaluation of pharmacokinetic parameters, safety and tolerability of single and multiple doses of Vespireit®: results of phase I clinical trial.
Objective: to evaluate the pharmacokinetic parameters, safety and tolerability of Vespireit® (INN buspirone), prolonged-release tablets, 15 mg (JSC “Valenta Pharm”, Russia), which is being developed as a drug for the treatment of functional vertigo, in healthy volunteers with a single oral dose of 15 and 30 mg on an empty stomach or after meals and multiple doses in a daily dose of 15 mg.Material and methods. JSC “Valenta Pharm” conducted an open-label, three-stage, randomized, two-periods, cross-over comparative clinical trial of Vespireit®. At stages 1 and 2, healthy volunteers were screened and randomized into two equal groups (Group 1 and Group 2), as well as the distribution of participants in Group 3. Then, at stage 1, healthy volunteers (n=24) took Vespireit® once at a dose of 15 mg on an empty stomach or after meals, at stage 2, volunteers (n=24) took Vespireit® once at a dose of 30 mg on an empty stomach or after meals. Stage 3 was conducted in 18 volunteers as a non-randomized, non-comparative study with Vespireit® 15 mg on an empty stomach once daily for 5 days. During the study, blood samples were collected from each subject to determine the concentration of test compounds in blood plasma and subsequently calculate their pharmacokinetic parameters. Quantitative determination of buspirone and its two metabolites, 6-hydroxybuspirone (6OH-bus) and 1-(2-pyrimidinyl)-piperazine (1-PP), was performed by a validated high-performance liquid chromatography method with tandem mass spectrometric detection. During the study, tolerability and safety were also evaluated: adverse events, vital signs, laboratory parameters and electrocardiogram parameters were recorded.Results. When the study drug Vespireit®, prolonged-release tablets, was administered once at a dose of 15 mg to healthy volunteers after a meal, an increase in the relative bioavailability and relative degree of absorption of buspirone was observed compared with the fasting state, which was accompanied by a 1.5- and 2.5-fold increase in the AUC0–t and Cmax of buspirone, respectively. In addition, the Cmax of 6-OH-bus increased 1.4-fold and the Cmax of 1-PP increased 1.2-fold. Meal had no effect on the AUC0–t of 6-OH-bus and 1-PP. When the study drug was administered once at a dose of 30 mg after a meal, an increase in the relative bioavailability and relative degree of absorption of buspirone was observed compared with fasting, which was accompanied by an increase in the AUC0–t and Cmax by 1.5- and 2.1-fold, respectively. A 1.2-fold increase in the Cmax of 6-OH-bus was also observed. Food had no effect on the AUC0–t of 6-OH-bus and on the AUC0–t and Cmax of 1-PP. No accumulation of buspirone and its metabolites was observed with repeated dosing.Conclusion. In the study, the values of pharmacokinetic parameters of the new drug Vespireit® in the prolonged-release tablets dosage form were determined both with single administration on an empty stomach and after meals and with multiple administration. The differences and advantages over buspirone preparations in the form of immediate-release tablets are shown: higher relative bioavailability of buspirone with a reduction in interindividual differences in bioavailability and Cmax, more stable plasma concentration of buspirone with reduced peak values of the active substance and metabolite 1-PP, a 1.2-fold increase in AUC0–∞, a 2-fold increase in T1/2, and a 2-fold increase in the degree of retardation (MRT) for buspirone, a 1.4-fold increase in Cmax and MRT of 6-OH-bus, a decrease in AUC0–∞, AUC0–t, and T1/2 of metabolite 1-PP, and a decrease in the ratio of the concentration of 1-PP to the concentration of buspirone and to 6-OH-bus. A favorable safety profile of Vespireit® was demonstrated.
- 6 May 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (1-2) , 19-25
Pharmacokinetics of Pentanedioic Acid Imidazolyl Ethanamide in Healthy Volunteers
Relevance. Pentanedioic acid imidazolyl ethanamide (PAIE) has been used clinically as an antiviral agent for a long time, however, there is no information in the available literature concerning the dependence of PAIE pharmacokinetics on isoenzymes polymorphism of the cytochrome P450 system (CYP), as well as on the variability of pharmacokinetic parameters in humans. The aim of the study is to determine the main pharmacokinetic parameters of PAIE in healthy volunteers and to assess the contribution of polymorphism of CYP P450 isoenzymes to the variability of pharmacokinetic parameters.Material and methods. The study included 12 healthy volunteers (5 men and 7 women) of the Caucasian race, who took In[1]gavirin® at a dose of 180 mg (2 capsules of 90 mg) on an empty stomach during two dosing periods, separated by a 7-day washout period. Determination of PAIE concentration in blood plasma and urine samples was carried out by high-performance liquid chromatography–mass spectrometry. Polymorphism of CYP genes was analyzed using the polymerase chain re[1]action method in order to analyze the pharmacogenetic features of PAIE metabolism in volunteers during the study.Results. After oral administration, PAIE quickly reached the systemic circulation: the maximum concentration of 578.88±145.21 ng/ml was observed after about 2 hours. Pharmacokinetic parameters of PAIE did not show high intraindividual variability and did not depend on polymorphism of isoenzymes CYP1A1, CYP2C9, and CYP2D6. Within 48 hours after the administration of the studied drug, about half of the taken dose of PAIE was excreted in the urine unchanged, which indicates a significant contribution of the kidneys to the elimination of PAIE. The only adverse event registered in 1 volunteer was a clinically insignificant decrease in the level of leukocytes, which did not require medical intervention and was resolved without consequences.Conclusion. PAIE is characterized by predictable pharmacokinetics, low intraindividual variability of pharmacokinetic parameters, and a favorable safety profile.
- 6 May 2021
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 66 (1-2) , 19-25
Pharmacokinetics of Pentanedioic Acid Imidazolyl Ethanamide in Healthy Volunteers
Relevance. Pentanedioic acid imidazolyl ethanamide (PAIE) has been used clinically as an antiviral agent for a long time, however, there is no information in the available literature concerning the dependence of PAIE pharmacokinetics on isoenzymes polymorphism of the cytochrome P450 system (CYP), as well as on the variability of pharmacokinetic parameters in humans. The aim of the study is to determine the main pharmacokinetic parameters of PAIE in healthy volunteers and to assess the contribution of polymorphism of CYP P450 isoenzymes to the variability of pharmacokinetic parameters.Material and methods. The study included 12 healthy volunteers (5 men and 7 women) of the Caucasian race, who took In[1]gavirin® at a dose of 180 mg (2 capsules of 90 mg) on an empty stomach during two dosing periods, separated by a 7-day washout period. Determination of PAIE concentration in blood plasma and urine samples was carried out by high-performance liquid chromatography–mass spectrometry. Polymorphism of CYP genes was analyzed using the polymerase chain re[1]action method in order to analyze the pharmacogenetic features of PAIE metabolism in volunteers during the study.Results. After oral administration, PAIE quickly reached the systemic circulation: the maximum concentration of 578.88±145.21 ng/ml was observed after about 2 hours. Pharmacokinetic parameters of PAIE did not show high intraindividual variability and did not depend on polymorphism of isoenzymes CYP1A1, CYP2C9, and CYP2D6. Within 48 hours after the administration of the studied drug, about half of the taken dose of PAIE was excreted in the urine unchanged, which indicates a significant contribution of the kidneys to the elimination of PAIE. The only adverse event registered in 1 volunteer was a clinically insignificant decrease in the level of leukocytes, which did not require medical intervention and was resolved without consequences.Conclusion. PAIE is characterized by predictable pharmacokinetics, low intraindividual variability of pharmacokinetic parameters, and a favorable safety profile.